Table 1. Comparison Between Rechallenge and Nonrechallenge Cases After an Immune-Related Adverse Event With at Least 1 Immune Checkpoint Inhibitor (n = 24 079) .
| Initial irAE | No. (%) | |
|---|---|---|
| Rechallenge after irAE (n = 6123) | No rechallenge after irAE (n = 17 956) | |
| ICI | ||
| Anti–PD-1 or anti–PD-L1 alone | 4360 (71.2) | 12 321 (68.6) |
| Anti–CTLA-4 alone | 791 (12.9) | 3290 (18.3) |
| Combination therapy | 972 (15.9) | 2345 (13.1) |
| Type of initial irAEa | ||
| Adrenal | 374 (6.1) | 815 (4.5) |
| Arthritis | 491 (8.0) | 1372 (7.6) |
| Colitis | 1745 (28.5) | 5353 (29.8) |
| Diabetes | 245 (4.0) | 511 (2.8) |
| Hematological | 92 (1.5) | 268 (1.5) |
| Hepatitis | 473 (7.7) | 1444 (8.0) |
| Hypophysitis | 353 (5.8) | 1136 (6.3) |
| Mucositis | 135 (2.2) | 374 (2.1) |
| Myocarditis | 102 (1.7) | 345 (1.9) |
| Myositis | 152 (2.5) | 455 (2.5) |
| Nephritis | 78 (1.3) | 198 (1.1) |
| Neurological | 424 (6.9) | 1243 (6.9) |
| Pancreatitis | 119 (1.9) | 332 (1.8) |
| Pneumonitis | 1288 (21.0) | 4001 (22.3) |
| Skin | 155 (2.5) | 478 (2.7) |
| Thyroiditis | 779 (12.7) | 1977 (11.0) |
| Uveitis | 97 (1.6) | 172 (1.0) |
| Vasculitis | 16 (0.3) | 48 (0.3) |
| Initial irAE | ||
| Serious | 5344 (87.3) | 14 846 (85.1) |
| Fatal | 643 (10.5) | 2037 (11.7) |
Abbreviations: CTLA-4, cytotoxic T-lymphocyte antigen-4; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; PD-1, programmed cell death 1; PD-L1, programmed cell death 1 ligand 1.
a
A case can have multiple initial irAEs; counts of initial irAEs exceeded the number of cases.